基化酶9A可以控制氧化物独立的cGMP和心脏病多变性
Dong I Lee1, Guangshuo Zhu1, Takashi Sasaki2
1Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA.
Nature
|March 25, 2015
概括
固酶类型9A (PDE9A) 调节了独立于氧化的心脏cGMP. 抑制PDE9A显示了对压力诱导的心脏病的治疗潜力.
科学领域:
- 心血管生物学 心血管生物学
- 分子信号传输的方法
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环氨酸单酸盐 (cGMP) 对于心血管信号传递至关重要,由固酶 (PDEs) 调节.
- 抑制PDE5A有助于心血管健康,但有局限性,其在心脏病中的作用与氧化 (NO) 信号传递有关.
- 调节心脏中尿素结合cGMP的特定PDEs仍然不清楚.
研究的目的:
- 研究PDE9A在心脏cGMP信号传递中的作用及其作为心脏病治疗点的潜力.
- 为了确定PDE9A是否调节心脏中的NO依赖或NO独立的cGMP通路.
主要方法:
- 在哺乳动物心脏中分析PDE9A的表达,包括人类样本.
- 在心脏肌细胞和肌肉模型中,PDE9A和PDE5A的遗传和药理抑制.
- 在PDE抑制后对蛋白质组和转录因子激活的分析.
- 对神经激素和压力过载压力的病理反应的治疗效应的评估.
主要成果:
- 在哺乳动物心脏中表达PDE9A,在过度缩小和心力衰竭中升高调节.
- PDE9A选择性地调节尿素刺激的cGMP,而不是NO刺激的cGMP.
- 抑制PDE9A可以防止病态心脏重塑,并逆转已确定的心脏病,独立于NO合成酶 (NOS) 活性.
- 与PDE9A抑制不同的是,PDE5A抑制需要活跃的NOS.
结论:
- PDE9A是心脏cGMP信号传递的关键调节者,与PDE5A的NO依赖通路不同.
- 抑制PDE9A为心脏病提供了一个有前途的治疗策略,特别是压力引起的疾病,通过独立于NO的作用.
- 向PDE9A代表了心血管疾病治疗的新方法.
更多相关视频
相关概念视频
Nitric Oxide Signaling Pathway
6.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
774
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
774
Transducer Mechanism: Enzyme-Linked Receptors
5.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
5.1K
Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Antianginal Drugs: Nitrates and β-Blockers
2.0K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
2.0K
Pulmonary Hypertension: Classification and Pathogenesis
898
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
898


